BR112018072020A2 - semaglutida em condições cardiovasculares - Google Patents

semaglutida em condições cardiovasculares

Info

Publication number
BR112018072020A2
BR112018072020A2 BR112018072020-8A BR112018072020A BR112018072020A2 BR 112018072020 A2 BR112018072020 A2 BR 112018072020A2 BR 112018072020 A BR112018072020 A BR 112018072020A BR 112018072020 A2 BR112018072020 A2 BR 112018072020A2
Authority
BR
Brazil
Prior art keywords
semagluted
cardiovascular conditions
cardiovascular
conditions
semaglutide
Prior art date
Application number
BR112018072020-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Kristian Højbjerg Hansen Oluf
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018072020(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of BR112018072020A2 publication Critical patent/BR112018072020A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
BR112018072020-8A 2016-04-28 2017-04-28 semaglutida em condições cardiovasculares BR112018072020A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16167458.5 2016-04-28
EP16167458 2016-04-28
EP16188262.6 2016-09-12
EP16188262 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Publications (1)

Publication Number Publication Date
BR112018072020A2 true BR112018072020A2 (pt) 2019-02-12

Family

ID=58668875

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072020-8A BR112018072020A2 (pt) 2016-04-28 2017-04-28 semaglutida em condições cardiovasculares

Country Status (24)

Country Link
US (3) US12569543B2 (https=)
EP (1) EP3448416B1 (https=)
JP (1) JP7221694B2 (https=)
KR (3) KR20180135012A (https=)
CN (1) CN109069589B (https=)
AU (2) AU2017256774B2 (https=)
BR (1) BR112018072020A2 (https=)
CA (1) CA3022535A1 (https=)
CL (1) CL2018003045A1 (https=)
DK (1) DK3448416T3 (https=)
ES (1) ES2928007T3 (https=)
HR (1) HRP20221150T1 (https=)
HU (1) HUE060040T2 (https=)
IL (1) IL262390B1 (https=)
MA (1) MA44762A (https=)
MX (1) MX2018012700A (https=)
MY (1) MY202967A (https=)
PH (1) PH12018502274B1 (https=)
PL (1) PL3448416T3 (https=)
RS (1) RS63630B1 (https=)
RU (1) RU2768283C2 (https=)
SI (1) SI3448416T1 (https=)
WO (1) WO2017186896A1 (https=)
ZA (2) ZA202507394B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7221694B2 (ja) 2016-04-28 2023-02-14 ノヴォ ノルディスク アー／エス 心血管状態におけるセマグルチド
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
HRP20230929T1 (hr) * 2018-10-26 2023-11-24 Novo Nordisk A/S Stabilni pripravci semaglutida i njihova upotreba
CN113194929B (zh) * 2018-12-21 2022-12-09 诺和诺德股份有限公司 Glp-1肽的喷雾干燥工艺
PE20230819A1 (es) * 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002316811A1 (en) * 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
WO2003084563A1 (en) * 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
TR201906789T4 (tr) 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP5662453B2 (ja) 2009-10-02 2015-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物の治療上の使用
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en) * 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX377589B (es) * 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2753642B8 (en) 2011-09-06 2017-12-13 Novo Nordisk A/S Glp-1 derivatives
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
US20150290294A1 (en) 2012-11-02 2015-10-15 Mansoor Husain Methods for inhibiting platelet aggregation using glp-1 receptor agonists
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
EP2968344A1 (en) 2013-03-15 2016-01-20 Boehringer Ingelheim International GmbH Use of linagliptin in cardio- and renoprotective antidiabetic therapy
MX369818B (es) * 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
JP7221694B2 (ja) * 2016-04-28 2023-02-14 ノヴォ ノルディスク アー／エス 心血管状態におけるセマグルチド

Also Published As

Publication number Publication date
IL262390B1 (en) 2023-05-01
PL3448416T3 (pl) 2022-11-07
KR102778218B1 (ko) 2025-03-10
US20250288649A1 (en) 2025-09-18
PH12018502274A1 (en) 2019-09-09
IL262390A (en) 2018-12-31
AU2017256774B2 (en) 2024-07-11
KR20250038818A (ko) 2025-03-19
ES2928007T3 (es) 2022-11-14
AU2017256774A1 (en) 2018-11-01
JP2019514925A (ja) 2019-06-06
JP7221694B2 (ja) 2023-02-14
EP3448416B1 (en) 2022-08-10
EP3448416A1 (en) 2019-03-06
HUE060040T2 (hu) 2023-01-28
CA3022535A1 (en) 2017-11-02
RU2018140900A (ru) 2020-05-28
WO2017186896A1 (en) 2017-11-02
ZA202507395B (en) 2025-09-25
HRP20221150T1 (hr) 2022-11-25
AU2024227113A1 (en) 2024-10-31
US20250262281A1 (en) 2025-08-21
RU2768283C2 (ru) 2022-03-23
RS63630B1 (sr) 2022-10-31
US20190134162A1 (en) 2019-05-09
ZA202507394B (en) 2025-09-25
CN109069589B (zh) 2022-09-06
KR20220147712A (ko) 2022-11-03
SI3448416T1 (sl) 2022-10-28
MA44762A (fr) 2019-03-06
US12569543B2 (en) 2026-03-10
PH12018502274B1 (en) 2024-02-28
CL2018003045A1 (es) 2018-12-14
MY202967A (en) 2024-05-31
RU2018140900A3 (https=) 2020-09-28
KR20180135012A (ko) 2018-12-19
CN109069589A (zh) 2018-12-21
MX2018012700A (es) 2019-01-30
DK3448416T3 (da) 2022-10-03

Similar Documents

Publication Publication Date Title
BR112018072020A2 (pt) semaglutida em condições cardiovasculares
CL2023000198A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CO2018006986A2 (es) Conjugado de acción prolongada del agonista triple receptor del glucagón /glp-1/gip
ZA201904616B (en) Glp-1 receptor agonists and uses thereof
CL2018000920A1 (es) Conjugados de anticuerpos que comprenden agonistas de receptor similares
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
CL2018000883A1 (es) Moduladores del receptor x farnesoide
BR112016013485A2 (pt) Método para preparar um produto lácteo tendo teor estável de galacto-oligossacarídeo(s)
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
MX2018005979A (es) Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico.
BR112018008045A2 (pt) micro-organismo recombinante que produz l-treonina e um método para produzir l-treonina com o uso do mesmo
CL2018001715A1 (es) Reguladores del cftr y métodos para su uso
BR112018008375A2 (pt) novos anti estrogênios heterocíclicos
MX2015009155A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
BR112018067344A2 (pt) liraglutida em condições cardiovasculares
ECSP16060194A (es) Formas de dosificación farmacéuticas
CL2018001716A1 (es) Reguladores del cftr y métodos para su uso
CL2018000420A1 (es) Nuevo derivado de catecol y composición farmacéutica que comprende el mismo.
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
郝俊杰 WIFI
庞泽欣 Think New
Karlsson et al. Externhandelns expansion: En (o) hållbar utveckling?
赵潇雨 Choose
UA92304U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства противодиабетического действия для терапии инсулиннезависимого сахарного диабета

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122022025361-0 PROTOCOLO 870220116295 EM 12/12/2022 16:31.

B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025010585-6 PROTOCOLO 870250043258 EM 26/05/2025 16:33.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]